People: ZELTIQ Aesthetics Inc (ZLTQ.O)
8 Dec 2016
Dr. Andrew N. Schiff, M.D., is an Independent Director of Zeltiq Aesthetics Inc., since July 2010. Dr. Schiff joined a Aisling Capital in September of 1999 and has served as a Managing Partner since 2002. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine at The New York Presbyterian Hospital where he maintains his position as a Clinical Assistant Professor of Medicine. In addition to ZELTIQ, Dr. Schiff currently serves as a Director of ARMGO Pharma, Inc., Colorscience, Dynova Laboratories, Inc., Agile Therapeutics, Inc. and Planet Technologies, Inc. Previously, Dr. Schiff served as a Director of Adams Respiratory Therapeutics, Inc., Barrier Therapeutics, Bioenvision, Inc., Cempra Pharmaceuticals, Inc., CardioKine, Inc., Miramar Laboratories, Inc., Myogen, Inc., SkinMedica, Inc., Sirion Therapeutics, Inc., and TransEnterix, Inc. Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia University, and his B.S. with honors in Neuroscience from Brown University.
|Total Annual Compensation, USD||57,500|
|Restricted Stock Awards, USD||174,952|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||--|
|Fiscal Year Total, USD||232,452|